Strategic Partners

Blazing a New Path in Medicine

Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Our small molecule drugs are designed to modulate protein levels in cells as a new therapeutic approach for cancer.

Nurix was founded by a team of internationally renowned experts in the fields of E3 ubiquitin ligase regulation and structure. Since its incorporation, Nurix has built a seasoned team of leaders with wide-ranging backgrounds in small molecule drug development and cancer therapy. Through its leadership in Targeted Protein Modulation and its powerful proprietary DELigase platform, Nurix has attracted industry-leading partners including its current drug discovery collaborations with Sanofi and Gilead Sciences.

Expanding Our Pipeline with Industry-Leading Partners

Our current strategic collaborations are focused on discovering and developing innovative therapies using our DELigase platform. Each collaboration addresses a unique set of targets chosen by our partner, is distinct from our proprietary pipeline, and employs our DELigase platform and Targeted Protein Degradation.

Sanofi

In January 2020, Nurix entered into a global strategic collaboration with Sanofi to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases. Read More

In January 2021, Nurix announced the expansion of its strategic collaboration with Sanofi, increasing the number of targets from three to a total of five. In connection with the expansion, Nurix received a payment of $22 million, in addition to the initial payment of $55 million. Read More

Gilead Sciences

In June 2019, Nurix entered into a global strategic collaboration with Gilead to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases. Read More

In March 2023, Gilead and Nurix announced that Gilead exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule, NX-0479, a potent, selective, oral IRAK4 degrader. Nurix received a payment of $20 million. Read More

Seagen

In September 2023, Nurix announced a strategic collaboration with Seagen, combining industry leading technologies of targeted protein degradation and antibody drug conjugation to advance an innovative new class of cancer therapeutics. Read More